search

Active clinical trials for "Huntington Disease"

Results 11-20 of 236

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease...

Huntington Disease

The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)

Recruiting22 enrollment criteria

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in...

Huntington DiseaseTardive Dyskinesia

This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.

Recruiting22 enrollment criteria

Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

Huntington Disease

This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration.

Recruiting16 enrollment criteria

Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease

Huntington Disease

Evaluate the safety and tolerability of combined oral thiamine with biotin therapy in patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate the biological effect of the treatment in the central nervous system of these patients using as the main biomarker the increase in the level of thiamine monophosphate (TMP) in cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up period of one year. Our main hypothesis is that combined thiamine-biotin oral therapy is a secure and well-tolerated treatment, potentially capable of modifying the disease course or avoiding the progression of symptoms in early-stages HD patients

Recruiting9 enrollment criteria

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's...

Huntington's Disease

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

Recruiting9 enrollment criteria

TEsting METformin Against Cognitive Decline in HD

Huntington Disease

Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with Huntington's disease. The study consists of a screening period (2 to 4 weeks), followed by a 52-week double-blind treatment period and a follow-up visit (one month after the end of treatment).

Recruiting24 enrollment criteria

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea...

ChoreaHuntington

This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.

Recruiting21 enrollment criteria

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Huntington Disease

The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.

Recruiting20 enrollment criteria

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Huntington Disease

Examine the effects of deutetrabenazine on functional speech and gait impairment

Recruiting19 enrollment criteria

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Spinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 31 more

The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.

Recruiting24 enrollment criteria
123...24

Need Help? Contact our team!


We'll reach out to this number within 24 hrs